ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
This Quarter Return
+3.78%
1 Year Return
+4.95%
3 Year Return
+16.8%
5 Year Return
+58.39%
10 Year Return
–
AUM
$245M
AUM Growth
+$245M
(+11%)
Cap. Flow
-$16.3M
Cap. Flow
% of AUM
-6.64%
Top 10 Holdings %
Top 10 Hldgs %
46.21%
Holding
76
New
23
Increased
14
Reduced
16
Closed
20
Top Buys
| 1 |
Esperion Therapeutics
ESPR
|
$9.4M |
| 2 |
Centene
CNC
|
$8.38M |
| 3 |
Medtronic
MDT
|
$6.95M |
| 4 |
ICU Medical
ICUI
|
$6.55M |
| 5 |
Ocular Therapeutix
OCUL
|
$6.29M |
Top Sells
| 1 |
Hologic
HOLX
|
$22.3M |
| 2 |
Pfizer
PFE
|
$16.7M |
| 3 |
Sanofi
SNY
|
$15.8M |
| 4 |
SI-BONE Inc
SIBN
|
$9.23M |
| 5 |
Cigna
CI
|
$6.62M |
Sector Composition
| 1 | Healthcare | 86.32% |
| 2 | Industrials | 2.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CALT
26
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
| $3.72M | 0.2% |
+160,218
| New | +$3.72M |
|
27
Baxter International
BAX
$12.1B
| $3.65M | 0.2% |
+42,439
| New | +$3.65M |
|
|
SYNH
28
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $3.18M | 0.17% |
+54,577
| New | +$3.18M |
|
|
MTEM
29
DELISTED
Molecular Templates, Inc.
MTEM
| $3.17M | 0.17% |
+15,321
| New | +$3.17M |
|
30
Aclaris Therapeutics
ACRS
$223M
| $2.8M | 0.15% |
1,728,787
-890,400
| -34% | -$1.44M |
|
31
Haemonetics
HAE
$2.57B
| $2.59M | 0.14% |
+28,937
| New | +$2.59M |
|
32
McKesson
MCK
$85.9B
| $2.45M | 0.13% |
15,942
-20,454
| -56% | -$3.14M |
|
33
Mustang Bio
MBIO
$11.1M
| $2.44M | 0.13% |
+1,025
| New | +$2.44M |
|
34
Universal Health Services
UHS
$11.6B
| $2.25M | 0.12% |
+24,178
| New | +$2.25M |
|
35
IQVIA
IQV
$31.4B
| $2.24M | 0.12% |
15,773
+7,441
| +89% | +$1.06M |
|
36
Bristol-Myers Squibb
BMY
$96.7B
| $2.12M | 0.12% |
36,109
-100,816
| -74% | -$5.93M |
|
37
Fate Therapeutics
FATE
$115M
| $2.09M | 0.11% |
60,892
+20,160
| +49% | +$692K |
|
|
PRNB
38
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| $1.82M | 0.1% |
30,395
+21,468
| +240% | +$1.28M |
|
39
Bio-Rad Laboratories Class A
BIO
$7.8B
| $1.58M | 0.09% |
+3,505
| New | +$1.58M |
|
40
Dentsply Sirona
XRAY
$2.77B
| $1.55M | 0.08% |
35,059
-17,586
| -33% | -$775K |
|
41
Becton Dickinson
BDX
$54.3B
| $1.46M | 0.08% |
6,232
-25,543
| -80% | -$5.96M |
|
|
FPRX
42
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.45M | 0.08% |
+237,174
| New | +$1.45M |
|
43
Sutro Biopharma
STRO
$85.6M
| $1.21M | 0.07% |
+156,005
| New | +$1.21M |
|
44
AdaptHealth
AHCO
$1.23B
| $1.14M | 0.06% |
71,000
-149,896
| -68% | -$2.41M |
|
45
PTC Therapeutics
PTCT
$4.41B
| $998K | 0.05% |
+19,677
| New | +$998K |
|
|
ZGNX
46
DELISTED
Zogenix, Inc.
ZGNX
| $799K | 0.04% |
29,575
-29,212
| -50% | -$789K |
|
|
TCRR
47
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $591K | 0.03% |
+38,494
| New | +$591K |
|
48
Insulet
PODD
$24.2B
| $479K | 0.03% |
+2,465
| New | +$479K |
|
|
ALXN
49
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $466K | 0.03% |
+4,148
| New | +$466K |
|
|
GNCA
50
DELISTED
Genocea Biosciences, Inc.
GNCA
| $276K | 0.02% |
119,979
-144,328
| -55% | -$332K |
|